NASDAQ: ORGSOrgenesis Inc Stock
$1.42+0.00 (+0%)
Updated Mar 24, 2023
ORGS Price
$1.42
Fair Value Price
$1.63
Market Cap
$39.04M
52 Week Low
$1.13
52 Week High
$4.04
P/E
2.41x
P/B
1.42x
P/S
1.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$36.03M
Earnings
-$14.89M
Gross Margin
24.9%
Operating Margin
-35.28%
Profit Margin
-41.3%
Debt to Equity
1.15
Operating Cash Flow
-$25M
Beta
0.83
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ORGS Overview
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ORGS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ORGS ($1.42) is undervalued by 12.97% relative to our estimate of its Fair Value price of $1.63 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ORGS ($1.42) is not significantly undervalued (12.97%) relative to our estimate of its Fair Value price of $1.63 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ORGS was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ORGS due diligence checks available for Premium users.
Be the first to know about important ORGS news, forecast changes, insider trades & much more!
ORGS News
Valuation
ORGS fair value
Fair Value of ORGS stock based on Discounted Cash Flow (DCF)
Price
$1.42
Fair Value
$1.63
Undervalued by
12.97%
ORGS ($1.42) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ORGS ($1.42) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ORGS was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ORGS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
2.41x
Industry
17.88x
Market
21.37x
ORGS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ORGS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ORGS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.42x
Industry
4.89x
ORGS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ORGS's financial health
Profit margin
Revenue
$13.6M
Net Income
-$4.1M
Profit Margin
-30.1%
ORGS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ORGS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$90.9M
Liabilities
$31.7M
Debt to equity
1.15
ORGS's short-term assets ($46.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ORGS's short-term assets ($46.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ORGS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.8M
Investing
-$6.7M
Financing
$19.5M
ORGS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ORGS vs Biotech Stocks
Orgenesis Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.